Eprenetapopt

Generic Name: Eprenetapopt

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇NO_₃

CAS Number: 5291-32-7

Unique Ingredient Identifier: Z41TGB4080

Background: Eprenetapopt has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Exploring Advancements in Higher-Risk MDS

Despite challenges in improving treatment for high-risk myelodysplastic syndrome (HR-MDS), advancements in combination therapies and molecular profiling offer hope. Allogeneic transplantation remains the only curative option, but posttransplant relapse is a concern. Recent trials combining azacitidine with various drugs showed promise but failed to outperform monotherapy in phase 3. Future potential lies in targeted treatments like azacitidine with venetoclax or tamibarotene, and refining response criteria. Molecular findings are crucial for more precise treatment design.

pmc.ncbi.nlm.nih.gov

2 years ago

Management of Patients with Lower-Risk Myelodysplastic Neoplasms

Myelodysplastic neoplasms (MDS) are clonal hematologic disorders with updated classifications in WHO 2022 and ICC 2022, incorporating genetic data for improved diagnosis and treatment. The International Prognostic Scoring System-Molecular (IPSS-M) enhances risk stratification. Treatments for lower-risk MDS aim to improve cytopenias, with new therapies like luspatercept and decitabine/cedazuridine approved. Ongoing clinical trials explore newer agents, emphasizing personalized therapy based on genetic and morphologic data.

Related Clinical Trials:

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden